Format

Send to

Choose Destination
J Infect Dis. 2016 Sep 1;214(5):748-52. doi: 10.1093/infdis/jiw253. Epub 2016 Jun 28.

Changes in Markers of T-Cell Senescence and Exhaustion With Atazanavir-, Raltegravir-, and Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.

Author information

1
David Geffen School of Medicine at UCLA.
2
Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
3
University of Wisconsin School of Medicine and Public Health, Madison.
4
Johns Hopkins University, Baltimore, Maryland.
5
Keck School of Medicine at the University of Southern California, Los Angeles.
6
Case Western Reserve University School of Medicine University Hospitals Case Medical Center, Cleveland, Ohio.

Abstract

It is unclear whether differential roles of CD4(+) versus CD8(+) T-cell senescence/exhaustion and effects of antiretroviral therapy (ART) on these processes may contribute to morbidity in treated human immunodeficiency virus type 1 (HIV) infection. In a prospective 96-week trial, 328 HIV-infected ART-naive participants were randomly assigned to receive tenofovir-emtricitabine plus either atazanavir/ritonavir, darunavir/ritonavir, or raltegravir. Markers of CD4(+) T-cell senescence (ie, the percentage of CD28(-)CD57(+) cells among CD4(+) T cells ) and CD4(+)/CD8(+) T-cell exhaustion (ie, the percentage of PD-1(+) cells among CD4(+)/CD8(+) T cells) decreased after ART. There were no changes in markers of CD8(+) T-cell senescence after ART and no differential changes in all markers in ART groups. Senescent CD4(+) and CD8(+) T cells may have differential roles in HIV pathogenesis.

KEYWORDS:

antiretroviral therapy; biomarkers; human immunodeficiency virus; immune activation; inflammation

PMID:
27354367
PMCID:
PMC4978379
DOI:
10.1093/infdis/jiw253
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center